Tag: report

CHICAGO, June 17, 2025 (GLOBE NEWSWIRE) -- Great Place To Work® and Fortune magazine have recognized Basis Technologies (https://basis.com) as one of this year’s Best Workplaces in Chicago. Basis Technologies is the industry’s leading advertising automation platform. This marks Basis’ 6th time being named to this prestigious list, ranking at No. 3. Earning a spot signifies that Basis has exceeded rigorous benchmarks, establishing itself as one of the top workplaces among companies headquartered in Chicago.

Kavango West 1X (Prospect I) rig mobilization to occur in June 2025

MONTREAL, June 17, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has completed the acquisition of the Paladin business, under the terms of the definitive Asset Purchase Agreement (“APA”) entered with Paladin Pharma Inc., an Endo, Inc. operating company, as announced in March 2025.

CHICAGO, June 17, 2025 (GLOBE NEWSWIRE) -- Consumers around the world are maximizing their snacking moments by savoring flavor, taste and texture while ensuring they are fully present, according to new findings from the sixth annual State of Snacking™ report published by Mondelēz International, Inc. (Nasdaq: MDLZ).

SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of  engineered T cell therapeutics that deploy phagocytic mechanisms, announces that the U.S. Food and Drug Administration (FDA) has granted CERo’s Orphan Drug Designation (ODD) for the company's lead drug candidate CER-1236, for the treatment of acute myeloid leukemia (AML). CER-1236 is an innovative therapy that engineers a cancer patient's own T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells.